Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 17Lymphoma 16Multiple Myeloma 13Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Melanoma 9Lung Neoplasms 9Prostatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, Non-Hodgkin 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neuroblastoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Follicular 4Burkitt Lymphoma 4Wilms Tumor 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Sarcoma 3Rhabdoid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Dexamethasone 4pomalidomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Calcium Dobesilate 2Bortezomib 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1ixazomib 1carfilzomib 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Lenalidomide 1Gemcitabine 1Busulfan 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Plasmacytoma × Biopsy × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡